The estimated Net Worth of Jennifer L. Carter is at least 94.6 千$ dollars as of 15 August 2022. Jennifer Carter owns over 10,500 units of Oncocyte stock worth over 94,550$ and over the last 3 years Jennifer sold OCX stock worth over 0$.
Sign up
Jennifer Carter OCX stock SEC Form 4 insiders trading
Jennifer has made over 2 trades of the Oncocyte stock since 2022, according to the Form 4 filled with the SEC. Most recently Jennifer bought 10,500 units of OCX stock worth 9,975$ on 15 August 2022.
The largest trade Jennifer's ever made was buying 10,500 units of Oncocyte stock on 15 August 2022 worth over 9,975$. On average, Jennifer trades about 6,833 units every 17 days since 2021. As of 15 August 2022 Jennifer still owns at least 30,500 units of Oncocyte stock.
You can see the complete history of Jennifer Carter stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jennifer Carter's mailing address?
Jennifer's mailing address filed with the SEC is C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE, CA, 92618.
Insiders trading at Oncocyte
Over the last 9 years, insiders at Oncocyte have traded over 16,389,842$ worth of Oncocyte stock and bought 56,056,405 units worth 102,313,246$ . The most active insiders traders include Partners, L.P.Broadwood Cap...、Cell Therapeutics, Inc. Lin...、Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of 3,382,106$. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth 10,001$.
What does Oncocyte do?
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
What does Oncocyte's logo look like?
Complete history of Jennifer Carter stock trades at Oncocyte
Oncocyte executives and stock owners
Oncocyte executives and other stock owners filed with the SEC include:
-
Ronald Andrews,
President, Chief Executive Officer, Director -
Lyndal Hesterberg,
Chief Scientific Officer -
Mitchell Levine,
Chief Financial Officer -
Ronald A. Andrews Jr.,
CEO, Pres & Director -
Cavan Redmond,
Independent Chairman of the Board -
Andrew Last,
Independent Director -
Andrew Arno,
Independent Director -
Melinda Griffith,
Independent Director -
Bob Yedid,
Investor Relations -
Douglas Ross,
Chief Medical Officer -
Padma Sundar,
Senior Vice President - Marketing and Market Access -
Tony Kalajian,
Senior Vice President, Chief Accounting Officer -
Albert Parker,
Chief Operating Officer -
Dr. Michael D. West Ph.D.,
Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. -
Dr. Ekkehard Schutz M.D., Ph.D.,
Chief Technology Officer -
Robert S. Seitz,
Head of Immune Oncology -
Li Yu,
VP, Controller & Principal Accounting Officer -
Gisela A. Paulsen,
Chief Operating Officer -
Sara Riordan,
Director of Medical Education -
Dr. Michael D. West,
Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. -
Dr. Douglas T. Ross M.D., Ph.D.,
Chief Science Officer -
William Annett,
Advisor -
Gisela Paulsen,
Former President and COO -
Vida Investments, Llc Kamen...,
-
Karen B. Chapman,
Vice President of Research -
Alfred D Kingsley,
Director -
Don M Bailey,
Director -
William Annett,
President and CEO -
Michael D West,
Director -
Kristine C. Mechem,
VP of Marketing -
Partners, L.P.Broadwood Cap...,
-
Anish M. John,
Chief Financial Officer -
Aditya P. Mohanty,
Director -
Cell Therapeutics, Inc. Lin...,
-
James Yang Liu,
Sr Dir., Cntlr, PAO, Int PFO -
Jennifer L. Carter,
Director -
Li Yu,
VP Cntrllr/Prncpl Acctng Offcr -
Partners, L.P.Bradsher Neal...,
-
Lou Silverman,
Director -
Josh Riggs,
CEO and President -
John Peter Gutfreund,
-
Andrea S. James,
Chief Financial Officer